Last reviewed · How we verify
NCT02111057
Perioperative Flare in RA: Characterization of Clinical and Biological Features
trial in Rheumatoid Arthritis in 162 participants. Completed in 9 May 2017.
9 May 2017
Quick facts
| Lead sponsor | Hospital for Special Surgery, New York |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 162 |
| Start date | 16 October 2013 |
| Primary completion | 9 May 2017 |
| Estimated completion | 9 May 2017 |
| Sites | 1 location across United States |
Conditions studied
- Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
Sponsor
Hospital for Special Surgery, New York
Who can join
Adults 18 to 90, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Researchers at the Hospital for Special Surgery are trying to learn more about post-operative rheumatoid arthritis flare (RA). This study hopes to understand RA flare after total joint replacement surgery and what the result of flaring is for patients over the 6 weeks post operation. Through this study we aim to describe rates, characteristics, and risk factors of RA flare within 6 weeks of total hip arthroplasty (THA) and total knee arthroplasty (TKA)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Patient-Reported Fatigue Associated with Joint Histopathology in Rheumatoid Arthritis.
Pearce-Fisher D, Smith MH, Mehta BY, Spolaore E, et al · · 2025 · PMID 39846130 · DOI 10.1002/acr2.11772
Verify or expand the search:
- PubMed search for NCT02111057
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rheumatoid Arthritis
Currently open trials in the same condition.
- NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
- NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
Other Hospital for Special Surgery, New York trials
Trials by the same sponsor.
- NCT07226700 — Suzetrigine in Total Hip Arthroplasty · Phase 3 · recruiting
- NCT06567873 — Gastric Ultrasound Assessment for Patients Taking Cannabis · completed
- NCT07217964 — Natural Matrix Protein · enrolling by invitation
- NCT06798493 — CSS-SR Validation Study · enrolling by invitation
- NCT06180486 — Mindfulness Meditation Intervention Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02111057 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital for Special Surgery, New York
- Last refreshed: 21 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02111057.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing